Clinical Trial Update: 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia [Phase 1]

View source ↗

Summary

NCI-sponsored Phase 1 clinical trial update of 6-Hydroxymethylacylfulvene (Irofulven) in patients with refractory acute myeloid leukemia, acute lymphoblastic le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Irofulven (irofulven)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED